Search

Search Constraints

You searched for: Author/Creator McArthur, Grant

Search Results

1. 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. (9th November 2020)

2. 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. (10th December 2020)

3. 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. (9th November 2020)

4. 548 CD8+ tissue-resident memory T cells are tumour reactive and increase after immunotherapy in a case of metastatic mucosal melanoma. (9th November 2020)

5. 548 CD8+ tissue-resident memory T cells are tumour reactive and increase after immunotherapy in a case of metastatic mucosal melanoma. (9th November 2020)

6. Adverse events 2.0—Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (May 2019)

7. An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic. Issue 4 (10th February 2021)

10. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. (February 2022)